Home / Peptides

Retatrutide

Also called: LY3437943

By The Health Stacks Research TeamUpdated July 28, 2026

Unapproved and investigational peptides, including popular weight-loss drugs like retatrutide, semaglutide, and tirzepatide, alongside recovery compounds like BPC-157 and TB-500, are entering the U.S.

through complex supply chains.

Many originate from unverified overseas manufacturers operating outside FDA oversight. While some peptides like semaglutide and tirzepatide are FDA-approved in commercial forms, the bulk active ingredients imported by third parties often bypass regulatory scrutiny, posing significant patient safety risks.

Research-stageEarly-stage — studied in cell or animal models, not yet tested in humans. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.
Where to Source Retatrutide
Tested purity COA available Fast shipping

What Retatrutide Helps With

The benefits people report — backed by research.

Glycemic & metabolic (48)

Helps regulate blood sugar 95/100· 3 srcGlycemic Control 95/100· 2 srcGlycaemic control 90/100· 2 srcTriple-receptor agonist targeting GIP, GLP-1, and glucagon receptors for fat loss 90/100· 2 srcTreatment of Type 2 Diabetes 85/100· 2 srcGlycaemic control in Type 2 Diabetes 95/100Improvement of body composition in type 2 diabetes 95/100Dose-dependent reductions in HbA1c and fasting glucose 95/100HbA1c reductions of up to 2.02% in participants with type 2 diabetes 95/100Glycaemic Improvement 95/100Improved glycemic control in Type 2 Diabetes 95/100Triple receptor agonist activity 90/100Improved metabolic outcomes 90/10072% reversal rate of prediabetes to normoglycemia 90/100Boosts energy 90/100Provides A1C reductions of up to 2.0% in type 2 diabetes 90/100Meaningful improvements across the lipid panel 90/100Triple GIP, GLP-1, and Glucagon Receptor Agonism 90/100Multi-receptor agonism produces synergistic metabolic effects greater than single receptor agonism 90/100Dose-dependent HbA1c reductions in type 2 diabetes 90/100Simultaneous activation of GIP, GLP-1, and glucagon receptors 90/100Activation of GLP-1, GIP, and Glucagon receptors 90/100Type 2 diabetes management 90/100Improved Glycaemic Control / HbA1c Reduction 90/100Improved glycemic control and HbA1c reduction 90/100Retatrutide lowers A1C by up to 2.0% in type 2 diabetes 88/100Glycemic improvements independent of diet 85/100Improvements in lipid profiles including ~40.6% reduction in triglycerides and ~26.9% in non-HDL cholesterol 85/100HbA1c reductions of up to 2.02% in type 2 diabetes 85/100Reversal of prediabetes to normoglycemia 85/100Supports liver health 85/100Triple agonism targeting GLP-1, GIP, and Glucagon receptors 85/100HbA1c reduction up to 2.16% in Type 2 Diabetes 85/100HbA1c reduction of up to 2.2 percentage points in type 2 diabetes 85/100Dose-dependent HbA1c reductions 85/100Triple-agonist activity targeting GLP-1, GIP, and glucagon receptors 85/100Improved cardiometabolic markers 85/100Triple Agonist Activity 85/100Reduction in A1c 85/100A1C reductions of 1.7% to 2.0% in Type 2 Diabetes 80/100Triple receptor agonism 75/100GLP-1 receptor agonists offer precision and specificity for chronic diseases 72/100Superior A1C reduction 72/100Average A1C reduction of up to 2.0% 72/100Boosts blood flow to injuries 70/100Triple-hormone receptor agonist activity 70/100A1C reduction 60/100Improved metabolic parameters 60/100

Weight management (43)

Appetite Suppression 90/100· 12 srcSupports weight loss 95/100· 9 srcAppetite suppression via GLP-1 receptor activation 72/100· 2 srcReduction in visceral adipose tissue 95/100Reduction of obesity 95/100Reduction in abdominal visceral and subcutaneous fat 95/100Helps regulate blood sugar 95/100Boosts energy 90/100Reduction in waist circumference 90/100Reduction in body fat 90/10065.3% of participants on 12 mg retatrutide achieved BMI <30 at 80 weeks 90/10065.3% of participants on 12 mg achieved BMI <30 90/100Preferential reduction of visceral adipose tissue 90/100Boosts blood flow to injuries 90/100Appetite suppression and satiety 90/100Fat mass reduction 90/100Visceral fat reduction 90/100Treatment for obesity and type 2 diabetes 90/100Fat Loss & Recomp 90/100Appetite suppression via GLP-1R agonism 85/100Adipose tissue mobilization and lipolysis 85/100Reduction of visceral adipose mass 85/100Thermogenesis and lipolysis activation 85/100Appetite suppression and reduced caloric intake 85/100Reductions in HbA1c and body mass index 85/100Rapid appetite suppression and elimination of food noise 85/100Appetite suppression and increased satisfaction with food 85/100Appetite suppression and increased satiety 85/100Supports liver health 85/100Appetite Suppression via GLP-1 activation 85/100Preserves lean body mass 85/100Decreased waist circumference 85/100Favorable body composition changes 80/100Fat Loss 80/100Combining retatrutide and semaglutide provides no additional receptor coverage or added benefit 75/100Mimics three hormones to regulate appetite 72/100Orforglipron enables oral daily dosing without food or water restrictions 72/100Appetite suppression via central nervous system pathways 70/100Best-in-class efficacy for obesity 70/100Best-in-class efficacy in phase III obesity trials 70/100Treatment of obesity 70/100Potential to better address obesity-related comorbidities like MASH via glucagon component 60/100Survodutide primarily reduces fat mass with minimal lean mass loss 60/100

Musculoskeletal (21)

Speeds muscle recovery 95/100Reduction in knee osteoarthritis pain 90/10075.8% reduction in osteoarthritis pain 90/100Reduces knee osteoarthritis pain by up to 73.1% 90/10075% reduction in knee osteoarthritis pain 90/100Supports weight loss 85/100Reduction in osteoarthritis pain 85/100Retatrutide reduces knee osteoarthritis pain by up to 73.1% 85/100Retatrutide reduces knee osteoarthritis pain by up to 75.8% 85/100Osteoarthritis pain relief 80/100Significant reduction in osteoarthritis pain 80/100Reduces inflammation 80/100Supports bone healing 80/100Improves sleep 75/100Statistically significant improvement in knee osteoarthritis pain and physical function 75/100Improvement in knee pain and physical function in obesity and knee osteoarthritis 75/100Improvement in Psoriatic Arthritis 72/100Sustained growth benefits for children with achondroplasia 72/100Improved WOMAC pain scores and physical function in knee osteoarthritis 72/100Improved joint outcomes 72/100Supports liver health 65/100

Cardiovascular & vascular (17)

Boosts blood flow to injuries 95/100Protection against cerebral ischemia-reperfusion injury 95/100Improvements in cardiometabolic risk factors 90/100Approximately 20% drop in LDL cholesterol 90/100Reduction in LDL cholesterol 85/100Reductions in triglycerides 85/100Discontinuation of antihypertensive medications 85/100Improved lipid profiles 85/100Reduction in blood pressure medication usage 85/100Lowered systolic blood pressure 85/100Improvements in cardiometabolic health measures 80/100Improvement in cardiometabolic risk markers 80/100Reduction in LDL cholesterol via PCSK9 degradation 75/100Improvement in heart failure with preserved ejection fraction 72/100Improvements in assessed cardiometabolic health measures 72/100Favorable changes in cardiometabolic markers 70/100Potential reduction in pulmonary hypertension risk 60/100

Antioxidant / oxidative stress (6)

Boosts energy 90/100Increased Fat Oxidation 85/100Increases fatty acid oxidation via glucagon receptor component 85/100Thermogenesis and hepatic fat oxidation via Glucagon receptor activation 85/100Fat Oxidation / Lipolysis 80/100Supports liver health 80/100

Renal & hepatic (5)

Supports liver health 95/100· 2 srcHepatic fat reduction 85/100· 2 srcHepatic fat mobilisation 90/100Improved body composition with preferential mobilization of visceral and hepatic fat 85/100Near-complete resolution of hepatic steatosis in some participants 80/100

Gastrointestinal & gut (5)

Heals gut issues 90/100Milder trial-reported GI side effect profile compared to semaglutide and tirzepatide 85/100Clinical remission at one year in 53% of Crohn's patients 85/100Better gastrointestinal tolerability than traditional GLP-1 receptor agonists 70/100Reduces nausea compared to GLP-1 monotherapy 70/100

Cancer / tumor (5)

Reduction in tumor volume 85/100Overcoming chemotherapy resistance in Triple-Negative Breast Cancer 85/100Anti-tumor effects in preclinical models 85/100Reduces tumor engraftment, delays tumor onset, and decreases tumor volume in pancreatic and lung cancer models 75/100Overcomes chemotherapy resistance in triple-negative breast cancer by suppressing O-GlcNAcylation of the YAP transcription factor 75/100

Neuroprotection & cognitive (4)

Speeds recovery 95/100Central nervous system effects 95/100Reduction in WOMAC pain scores 80/100Reduction in pain and improvement in physical function 80/100

Skin, hair & cosmetic (4)

Melanotropic effects / Melanocortin receptor agonism 95/100First targeted oral peptide therapy for moderate-to-severe plaque psoriasis 90/100Follicular cell signaling / Hair growth 85/10075% improvement in overall disease severity EASI-75 in atopic dermatitis 85/100

Anti-inflammatory (4)

Reduces inflammation 85/100Reduction of Pro-inflammatory Cytokines 85/100Beta-cell Protection in Cytokine Stress Models 85/100Reductions in blood pressure and inflammatory markers 80/100

Antimicrobial & antiviral (3)

Supports liver health 95/100Prevention of RSV lower respiratory tract disease 85/100Bacteriostatic water provides multi-dose stability by inhibiting microbial growth 72/100

Tissue & wound healing (3)

Boosts blood flow to injuries 95/100Tissue repair research 85/100Boosts collagen production 85/100

Performance & recovery (3)

Prolonged stimulation of GH and IGF-I secretion 95/100Improvements in physical function 90/100Growth hormone secretion 85/100

Immune modulation (3)

Promotion of Regulatory T-cells 85/100Strengthens immunity 85/100Targeted degradation of BTK protein in chronic lymphocytic leukemia 72/100

Other Benefits (10)

Boosts energy 90/100· 6 srcRegenerative and protective actions via gene regulation 95/100Reduces apnea-hypopnea index by 60.6% in moderate-to-severe OSA 85/100Lower discontinuation rate due to side effects at 4mg compared to placebo 85/100Triglyceride reduction of up to 42.4% 85/100Significant reduction in number and size of duodenal polyps in FAP 70/100Reduction in MASH and fibrosis biomarkers 95/100Selective growth hormone secretion 95/100Effect on biomarkers of aging and life span extension 95/100Improves sleep 90/100
Retatrutide — weight loss

How People Use It

Under the skin

  • 5mg vial + 2mL BAC water (2,500 mcg/mL) or 10mg vial + 2mL BAC water (5,000 mcg/mL)

For research purposes only. Not medical advice. Talk to a doctor before use.

Get Retatrutide for Your Research

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Find Retatrutide Research Suppliers
Tested purity COA available Fast shipping
Technical Details & Research (click to expand)

Known Side Effects

All Dosing Protocols

CagriSema — SubQ 95/100

Research Citations (91)

  • Retatrutide’s mechanisms of action

    95/100
    Source

  • The First Triple Agonist for Antiobesity: Retatrutide

    2024 95/100
    Source

  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    2018 95/100
    Source

  • Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

    2023 95/100
    Source

  • LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

    2022 95/100
    Source

  • Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor

    2024 95/100
    Source

  • European guidelines on diagnosis and treatment of phenylketonuria: First revision

    2025 90/100
    Source

  • PKU dietary handbook to accompany PKU guidelines

    2020 90/100
    Source

  • The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

    2024 95/100
    Source

  • Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation

    2025 95/100
    Source

  • Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

    2023 95/100
    Source

  • Efficacy and safety of retatrutide for the treatment of type 2 diabetes: a phase 2 trial

    95/100
    Source

  • The effect of glucagon on energy expenditure in humans

    90/100
    Source

  • A role for glucagon-like peptide-1 in the central regulation of feeding

    90/100
    Source

  • Phase III TRIUMPH-1 trial

    90/100
    Source

History & Milestones

Key moments in Retatrutide’s research and regulatory timeline — sourced and dated.

  1. European guidelines on diagnosis and treatment of phenylketonuria: First revisionPublicationJan 1, 2025
    90/100↗ source
  2. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidationPublicationJan 1, 2025
    95/100↗ source
  3. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronPublicationJan 1, 2024
    95/100↗ source
  4. The First Triple Agonist for Antiobesity: RetatrutidePublicationJan 1, 2024
    95/100↗ source
  5. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptorPublicationJan 1, 2024
    95/100↗ source
  6. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesPublicationJan 1, 2023
    95/100↗ source
  7. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAPublicationJan 1, 2023
    95/100↗ source
  8. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptPublicationJan 1, 2022
    95/100↗ source
  9. PKU dietary handbook to accompany PKU guidelinesPublicationJan 1, 2020
    90/100↗ source
  10. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptPublicationJan 1, 2018
    95/100↗ source

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, dosing at a glance, and what the research says — one page, one email.

No spam. Unsubscribe anytime.

Related on The Health Stacks

Explore by goal

GLP-1 & Metabolic Peptides

Related peptides

SemaglutideTirzepatideMOTS-c

Compare

Retatrutide vs Tirzepatide Retatrutide vs Semaglutide